Back to Journals » Journal of Experimental Pharmacology » Volume 11

Bioactive fraction from Lagerstroemia speciosa leaves (DLBS3733) reduces fat droplet by inhibiting adipogenesis and lipogenesis

Authors Karsono AH, Tandrasasmita OM, Tjandrawinata RR

Received 30 July 2018

Accepted for publication 5 March 2019

Published 2 May 2019 Volume 2019:11 Pages 39—51

DOI https://doi.org/10.2147/JEP.S181642

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Professor Bal Lokeshwar


Agung Heru Karsono, Olivia Mayasari Tandrasasmita, Raymond Rubianto Tjandrawinata

Section of Molecular Pharmacology, Department of Research Innovation and Invention, Dexa Laboratories of Biomolecular Sciences, Dexa Medica, Cikarang, West Java, Indonesia

Background: Obesity has become a risk factor for metabolic diseases. One of the cellular characteristics of obesity is the occurrence of adipose cells hyperplasia. Lagerstroemia speciosa is a plant which has been used for the treatment of diabetes. Furthermore, some studies also indicated that L. speciosa possesses antiobesity activity. Its antiobesity activity was examined in the present study through adipogenesis, lipogenesis, and lipolysis pathways.
Aim: DLBS3733, a bioactive fraction of L. speciosa, was explored for its potential benefits to alter obesity through adipogenesis and lipogenesis inhibition and lipolysis induction activity.
Materials and methods: This study was performed using 3T3-L1 cells. mRNA level and protein expressions related to adipogenesis, lipogenesis, and lipolysis pathways were assayed in this study.
Results: Antiadipogenic effects of DLBS3733 (15 μg/mL) were found to be mediated by a significant downregulation of mRNA level of multicomponents involved in adipogenesis which include C/EBPα (CCAAT/enhancer-binding protein alpha) and PPAR-γ (peroxisome proliferator-activated receptor gamma) by 75% and 80.1% (p<0.05), respectively. DLBS3733 was found to inhibit lipogenesis, as shown by the significant reductions of adiponectin excretion and mRNA level of fatty acid synthase, SREBP (sterol regulatory element-binding protein), and ACC-β (Acetyl-CoA carboxylase) by 44.7%, 70.9%, and 83.1%, respectively (p<0.05). In addition, DLBS3733 was found to inhibit fat droplets accumulation in the cells in a dose-dependent manner through Oil-Red O staining. pAMPK protein was upregulated by 75% and ACC-β was downregulated by 88% (p<0.05) which indicates the reduction of lipid synthesis. Meanwhile, DLBS3733 showed an insignificant effect on adipose triglyceride lipase, hormone-sensitive lipase, and carnitine palmitoyl-CoA transferase-1 which indicate that DLBS3733 does not induce lipolysis.
Conclusion: These results demonstrate the inhibitory activity of DLBS3733 on adipogenesis and lipogenesis. DLBS3733 may provide an effective and potential benefit in the prevention of obesity.

Keywords: Lagerstroemia speciosa, obesity, adipogenesis, lipogenesis, adiponectin, ACC-β

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]